Proactive Investors - Run By Investors For Investors

PharmAust growing Epichem while working to repurpose drug in animals and humans

PharmAust Ltd (ASX:PAA) executive chairman Dr Roger Aston tells Proactive Investors that the pharmaceutical company is divided into two branches.

One branch is the wholly-owned subsidiary Epichem, which provides services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries. It has projected sales of three to four million dollars this year, with expectations that the figure will grow substantially following significant expansion in the past twelve months. 

The second branch involves drug repurposing, currently focused on  Monepantel (MPL). PharmAust is working to establish the veterinary parasite medicine as an oncology treatment for dogs. At the same time, it is working to cross over into human cancer fighting applications.

 
View full PAA profile View Profile

PharmAust Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use